San Jose, California (PRWEB) July 05, 2012
Follow us on LinkedIn New fields and applications in medicine and biology are becoming a reality beyond genomic sequencing. In areas such as oncology, DNA sequencing gained prime importance as the identification of gene rearrangements and new mutations is capable of providing greater insight into probable drug discovery areas as well as disease mechanisms. The market continues to witness rapid changes with the introduction and upgrade of second generation sequencers. The growth in revenue of the segment is high and the current level of growth is expected to continue in the near future. The introduction of Next Generation Sequencing (NGS) technologies about a decade back, had a huge impact on the genomic research sphere as a whole. Some of the innovative current Sequencing projects utilizing NGS technology include the sequencing of numerous unique samples, tumors as well as individuals. NGS technologies have been used for standard sequencing applications, such as genome sequencing and resequencing, and for novel applications previously unexplored by Sanger sequencing. High degree of vitality, inventiveness, and dynamism characterize the evolving NGS market. Roche’s 454 Sequencing Systems generate thousands of superior sequencing reads within hours, as well as provides medical value in resequencing applications for oncology and virology research.
The global market is witnessing significant growth by strongly diversifying into labs that were previously not involved in sequencing. Additionally, NGS technologies are expected to continue impinging upon the usage of DNA microarray until the costs come down. The NGS market is forecast to grow due to the advent of new technology applications and the rapid pace in the advancement of sequencer technology. The introduction of new technologies brought about a shift in the NGS field from basic to applied research, while advances in sequencer platforms resulted in rapid democratization of technology as well as a decrease in the costs incurred in nucleotide sequencing. Further expansion of the NGS market is expected to be fueled by product cycles in the market, broadening of applications carried out by the sequencer to replace associated products such as gene-expression arrays as well as increased penetration of NGS applications into the traditional sequencer market.
Traditionally, DNA sequencing was used in clinical trials in a limited manner till date, owing to the huge amount of time and prohibitive costs associated with analyzing large data base. However over the past two decades, a substantial deceleration in the overall cost burden associated with Genome Sequencing paved way for their wide usage in high value clinical service providing labs and biomedical research worldwide, thus shifting focus of the technologys application from basic research to applied research. Till some time back, the cost of sequencing using first and second generation sequencers was extremely high and practically unaffordable by the biomedical research community and clinical labs. The sequencing costs however, have since declined steeply with the emergence of next generation sequencers, and now stand at a whopping 90% lesser than what they were two decades back, making them affordable and etching a path for the technologys wide usage.
In future, next-generation sequencing technologies are expected to exercise a significant impact on plant/crop genetics. The growth of large-scale genomic resources such as molecular markers, sequence and transcript data, and physical and genetic maps are also likely to play a vital role. Genome and transcriptome sequencing (both de novo and resequencing) for crop plants using NGS is improving. NGS technologies led to an increase in the availability of genomic data for crops such as pigeon pea and chickpea. Availability of genetic markers developed using NGS technologies is enabling trait mapping, as well as making marker-assisted propagation more viable. Apart from enabling genomics assisted breeding, NGS is also expected to drive the growth of transformational technologies for several crop species.
Developed markets such as United States and Western Europe represent two of the largest markets worldwide, as stated by the new market research report on Next Generation Sequencers (NGS). Asia-Pacific, driven by promising growth from rapidly evolving markets of China and India, offers tremendous growth opportunities and is slated to expand at a strong CAGR of over 27% through 2018. China represents significant potential for clinical genotyping services due to its extensive biotechnology and pharmaceutical infrastructure as well as multitude of clinical trials performed in the region.
Key players profiled in the report include Agilent Technologies, Inc., Ambry Genetics Corp., BioNano Genomics, Inc., Caliper Life Sciences, Inc., Covaris, Inc., F. Hoffman-La Roche Ltd., 454 Life Sciences, Genomic Health, Inc., Helicos BioSciences Corporation, Illumina, Inc., IntegenX, Inc., Life Technologies Corporation, NuGen Technologies, Inc., among others.
The research report titled Next Generation Sequencers (NGS): A Global Strategic Business Report announced by Global Industry Analysts Inc., provides a comprehensive industry overview, market challenges, application areas, competition, technology overview, recent industry activity, and profiles of major/niche global market participants. The report provides annual revenue estimates and projections for the years 2009 through 2018 in value (US$ ) terms for geographic markets including the US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World.
For more details about this comprehensive market research report, please visit
About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a leading publisher of off-the-shelf market research. Founded in 1987, the company currently employs over 800 people worldwide. Annually, GIA publishes more than 1300 full-scale research reports and analyzes 40,000+ market and technology trends while monitoring more than 126,000 Companies worldwide. Serving over 9500 clients in 27 countries, GIA is recognized today, as one of the world’s largest and reputed market research firms.
Follow us on LinkedIn
Global Industry Analysts, Inc.
Web Site: http://www.StrategyR.com/